US-based biotechnology company BrainStorm Cell Therapeutics has partnered with contract development and manufacturing ...

The US Food and Drug Administration (FDA) has granted clearance to BrainStorm Cell Therapeutics to commence a Phase IIIb ...

autologous dopamine neuron cell therapy. Following this FDA approval for the phase 1 clinical trial, the NRI's innovative preclinical work was translated into the clinic with the first patient ...

XellSmart's off-the-shelf, allogeneic, clinical-grade iPSC-derived cell therapy (XS228) for ALS has been approved by the FDA to enter Phase I clinical trials, making it the first-in-class regenerative ...

The CAR T cell therapy in this phase I trial uses the patient's own T cells, modified in the lab to target the CD5 protein, which is highly expressed in T cell lymphoma and in normal T cells.